openPR Logo
Press release

Pulmonary Drugs Market Continues Growth | 2018 Key Players are Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc.

09-21-2018 08:23 AM CET | Science & Education

Press release from: Coherent Market Insights

Pulmonary Drugs Market Continues Growth | 2018 Key Players

The major manufacturers are focused towards development of new and innovative products with extensive R&D on pulmonary drugs. For instance, in 2017, Sanofi SA completed the phase II clinical trials in April 2017 of new drug Dupilumab in association with Regeneron Pharmaceuticals. The drug is indicated for the treatment of uncontrolled asthma in children and is expected to complete its clinical trial studies in January, 2021. Moreover, in 2017, Circassia Pharmaceuticals completed Phase IV clinical trials of Tudorza with a collaborative agreement between Circassia and AstraZeneca Plc. for the treatment of COPD.

Ask Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/1285

Increasing prevalence of chronic obstructive pulmonary diseases and other respiratory diseases across the world is one of the leading causes of death and disability. Thus, the prevention, treatment, and control of these diseases is one of the top priorities for governments and players in the healthcare sector. According to the Forum of International Respiratory Societies, in 2016, around 65 million people were suffering from chronic obstructive pulmonary disease worldwide, leading to 3 million deaths. Moreover, around 334 million people suffered from asthma, which is the most common chronic respiratory condition among children as well as adults. A wide range of conditions are included within the ambit of pulmonary diseases that include pneumonia, allergic rhinitis, pulmonary hypertension, and others that are responsible for creating a giant economic burden on the healthcare sectors of most of nations. Pulmonary drugs are focused towards providing medications for all these types of diseases leading to expected market growth in near future. According to the World Health Organization, 2017, Chronic Obstructive Pulmonary Diseases (COPD) is responsible for about 5% of the total deaths worldwide in 2015. Furthermore, according to the Office of Disease Prevention and Health Promotion 2014, 25 million patients in the U.S. had asthma that led to an estimated annual expenditure for asthma turning around to US$ 20.7 billion. Thus, the constant rise in the number patients suffering with respiratory diseases are expected to surge the market growth over the forecast period.

The Global Pulmonary Drugs Market, by Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, and Others), by Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 28,064.5 million in 2016 and is projected to exhibit a CAGR of 8.1% over the forecast period (2017 – 2025), as highlighted in a new report published by Coherent Market Insights. The pulmonary drugs market is expected to gain significant traction with patent expiry of branded drugs, which is expected to generate opportunities for the market players and robust number of drug candidates in the pipeline as a result of extensive R&D.

Ask for customization: www.coherentmarketinsights.com/insight/request-customizat...

The key players adopt the strategies of mergers, definitive agreements, and acquisitions to expand the respiratory drugs product portfolio, thereby increasing market share. For instance, in 2015, AstraZeneca Plc entered into a definitive agreement with Takeda Pharmaceutical Company Limited, under which AstraZeneca acquired the core respiratory business of Takeda to strengthen respiratory therapeutic portfolio. Furthermore, in 2016, Mylan N.V. acquired Meda Pharmaceuticals to enhance geographic reach with significant sales of products worldwide, in which China, South East Asia, and Middle East were the major regional targets for the company.

Key Takeaways of the Pulmonary Drugs Market:

The global pulmonary drugs market is expected to exhibit a CAGR of 8.1% over the forecast period, owing to the presence of high potential market and increasing prevalence of chronic respiratory diseases in Asia Pacific, Latin America, the Middle East, and Africa

Among drug class, inhaled corticosteroids segment holds a dominant position attributed to the advantages offered by the drugs that include lower concentration of drug delivery into the patient’s system allowing even distribution as well as lower risk of side effects that are usually exhibited by oral steroid consumption

Else place an Inquire before Purchase “Non-Surgical Skin Tightening Market Size, Status and Forecast 2026 : www.coherentmarketinsights.com/insight/talk-to-analyst/1285

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pulmonary Drugs Market Continues Growth | 2018 Key Players are Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc. here

News-ID: 1253316 • Views:

More Releases from Coherent Market Insights

Protocol Analyzer Market Unveiling the Future | Global Market Insights, Trends & Opportunities 2025-2032
Protocol Analyzer Market Unveiling the Future | Global Market Insights, Trends & …
The Protocol Analyzer market is estimated to be valued at USD 4.64 Bn in 2025 and is expected to reach USD 10.65 Bn by 2032, growing at a compound annual growth rate CAGR of 12.6% from 2025 to 2032. ➤ The latest report published by Coherent Market Insights highlights the growth prospects of the Protocol Analyzer Market from 2025 to 2032. In-depth research on Industry Size, Share, Business Analysis, Growth Factors,
Home Shopping Services Market is Going to Boom: Strategic Insights and Growth Opportunities with Key Players like Amazon.com, Inc. and eBay Inc.
Home Shopping Services Market is Going to Boom: Strategic Insights and Growth Op …
The Home Shopping Services market is estimated to be valued at USD 6.73 Bn in 2025 and is expected to reach USD 19.96 Bn by 2032, growing at a compound annual growth rate CAGR of 16.8% from 2025 to 2032. ➤ The Home Shopping Services Market Research Report covers a wide range of aspects, such as industry growth, revenue, development, segments, companies and progress, main trends, market dynamics, challenges, standards, deployment
Antibodies Contract Manufacturing Market Set for Dynamic Boom as Key Players Amgen Inc, Lonza Group, Celerion
Antibodies Contract Manufacturing Market Set for Dynamic Boom as Key Players Amg …
The Antibodies Contract Manufacturing market is estimated to be valued at USD 21.61 Bn in 2025 and is expected to reach USD 42.68 Bn by 2032, growing at a compound annual growth rate CAGR of 10.2% from 2025 to 2032. ➤ The latest report "Antibodies Contract Manufacturing 2025 by Key Players, Regions, Types and Applications, Forecast to 2032" from Coherent Market Insights provides a detailed and comprehensive analysis of the Antibodies
Medical Marijuana Market Future Business Opportunities 2025-2032 | Tilray, Aphria Inc.
Medical Marijuana Market Future Business Opportunities 2025-2032 | Tilray, Aphri …
The Medical Marijuana market is estimated to be valued at USD 25.54 Bn in 2025 and is expected to reach USD 65.13 Bn by 2032, growing at a compound annual growth rate CAGR of 14.3% from 2025 to 2032. ➤ The market research report on the Medical Marijuana industry offers essential insights into growth trends and primary revenue drivers anticipated from 2025 to 2032. It delves into various factors influencing the

All 5 Releases


More Releases for Pulmonary

Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028. The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027. Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion. Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated
03-15-2017 | Health & Medicine
TMR
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments